Vanguard Group
CCCC icon

Vanguard Group’s C4 Therapeutics CCCC Stock Holding History

Vanguard Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.37M Buy
4,379,815
+1,188,258
+37% +$2.81M ﹤0.01% 3049
2025
Q3 		$7.09M Buy
3,191,557
+173,535
+6% +$417K ﹤0.01% 3155
2025
Q2 		$4.32M Sell
3,018,022
-352,858
-10% -$513K ﹤0.01% 3260
2025
Q1 		$5.39M Buy
3,370,880
+24,907
+0.7% +$74.3K ﹤0.01% 3141
2024
Q4 		$12M Sell
3,345,973
-24,708
-0.7% -$123K ﹤0.01% 2854
2024
Q3 		$19.2M Sell
3,370,681
-186,018
-5% -$1.12M ﹤0.01% 2606
2024
Q2 		$16.4M Buy
3,556,699
+636,671
+22% +$3.8M ﹤0.01% 2659
2024
Q1 		$23.9M Buy
2,920,028
+920,627
+46% +$7.14M ﹤0.01% 2515
2023
Q4 		$11.3M Buy
1,999,401
+74,545
+4% +$170K ﹤0.01% 2874
2023
Q3 		$3.58M Buy
1,924,856
+24,500
+1% +$74.7K ﹤0.01% 3386
2023
Q2 		$5.23M Sell
1,900,356
-212,170
-10% -$682K ﹤0.01% 3275
2023
Q1 		$6.63M Buy
2,112,526
+47,611
+2% +$280K ﹤0.01% 3171
2022
Q4 		$12.2M Buy
2,064,915
+45,261
+2% +$375K ﹤0.01% 2864
2022
Q3 		$17.7M Buy
2,019,654
+58,941
+3% +$612K ﹤0.01% 2682
2022
Q2 		$14.8M Sell
1,960,713
-61,429
-3% -$541K ﹤0.01% 2788
2022
Q1 		$49.1M Buy
2,022,142
+5,683
+0.3% +$138K ﹤0.01% 2318
2021
Q4 		$64.9M Buy
2,016,459
+77,884
+4% +$3.08M ﹤0.01% 2208
2021
Q3 		$86.6M Buy
1,938,575
+531,735
+38% +$22.8M ﹤0.01% 2061
2021
Q2 		$53.2M Buy
1,406,840
+1,018,882
+263% +$36.5M ﹤0.01% 2339
2021
Q1 		$14.4M Sell
387,958
-64,209
-14% -$2.55M ﹤0.01% 2959
2020
Q4 		$15M Buy
+452,167
New +$13.1M ﹤0.01% 2783

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group's CCCC Position: Q4 2025 in Review

Vanguard Group increased its C4 Therapeutics (CCCC) stake by 37% in Q4 2025, buying an estimated $2.81M and bringing the position to 4,379,815 shares worth $8.37M. The position accounts for ﹤0.01% of the portfolio, ranked #3049.

Vanguard Group first reported a position in CCCC in Q4 2020 and has held it in 21 quarters since. The position peaked at $86.6M in Q3 2021. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • Vanguard Group held 4,379,815 shares of C4 Therapeutics worth $8.37M as of Q4 2025.
  • Vanguard Group bought 1,188,258 C4 Therapeutics shares in Q4 2025, an estimated $2.81M.
  • C4 Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3049 holding.
  • Vanguard Group first reported a position in C4 Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's C4 Therapeutics position peaked at $86.6M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.